MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis
June 28, 2022 03:00 ET
|
MRM Health NV
GHENT, Belgium, June 28, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they...
MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis
June 07, 2022 03:00 ET
|
MRM Health NV
GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication...
MRM Health to Present at the 6th Microbiome Movement Drug Development Europe Summit
January 26, 2022 03:00 ET
|
MRM Health NV
GHENT, Belgium, Jan. 26, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that it will...
MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis
December 08, 2021 03:00 ET
|
MRM Health NV
GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first...
MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis
September 28, 2021 03:00 ET
|
MRM Health NV
GHENT, Belgium, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received...